|
TCEB3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.45600000003954E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.45249999997199E-06 |
| Normal-vs-Stage2 |
1.093390E-01 |
| Normal-vs-Stage3 |
7.20449999658257E-08 |
| Normal-vs-Stage4 |
3.95100000050164E-07 |
| Stage1-vs-Stage2 |
2.875800E-02 |
| Stage1-vs-Stage3 |
5.413900E-02 |
| Stage1-vs-Stage4 |
7.469900E-02 |
| Stage2-vs-Stage3 |
1.559600E-03 |
| Stage2-vs-Stage4 |
2.520300E-03 |
| Stage3-vs-Stage4 |
7.790600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.02399999882763E-08 |
| Normal-vs-AfricanAmerican |
3.553900E-02 |
| Normal-vs-Asian |
3.17809999994534E-06 |
| Caucasian-vs-AfricanAmerican |
2.055200E-01 |
| Caucasian-vs-Asian |
6.244600E-01 |
| AfricanAmerican-vs-Asian |
1.242210E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.46309999996086E-06 |
| Normal-vs-Female |
7.81020000006905E-07 |
| Male-vs-Female |
6.437600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.55353999999885E-05 |
| Normal-vs-Age(41-60Yrs) |
4.14199999998477E-06 |
| Normal-vs-Age(61-80Yrs) |
4.69709999995072E-06 |
| Normal-vs-Age(81-100Yrs) |
9.464700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.361400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.770000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.967400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.802200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.309200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.224200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.045670E-04 |
| Classical-VS-Follicular |
5.561000E-03 |
| Classical-VS-Other |
4.110800E-01 |
| Classical-VS-Normal |
2.47160000022006E-07 |
| Tall-VS-Follicular |
1.62510000012439E-07 |
| Tall-VS-Other |
3.519400E-01 |
| Tall-VS-Normal |
4.92849983046995E-10 |
| Follicular-VS-Other |
1.125250E-01 |
| Follicular-VS-Normal |
5.089800E-02 |
| Other-VS-Normal |
1.058050E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.21770000000166E-05 |
| Normal-vs-N1 |
1.23179999977907E-07 |
| N0-vs-N1 |
1.233810E-02 |
|
|
